Literature DB >> 10536003

Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

X Jiang1, A Lopez, T Holyoake, A Eaves, C Eaves.   

Abstract

Primitive subsets of leukemic cells isolated by using fluorescence-activated cell sorting from patients with newly diagnosed Ph(+)/BCR-ABL(+) chronic myeloid leukemia display an abnormal ability to proliferate in vitro in the absence of added growth factors. We now show from analyses of growth-factor gene expression, protein production, and antibody inhibition studies that this deregulated growth can be explained, at least in part, by a novel differentiation-controlled autocrine mechanism. This mechanism involves the consistent and selective activation of IL-3 and granulocyte colony-stimulating factor (G-CSF) production and a stimulation of STAT5 phosphorylation in CD34(+) leukemic cells. When these cells differentiate into CD34(-) cells in vivo, IL-3 and G-CSF production declines, and the cells concomitantly lose their capacity for autonomous growth in vitro despite their continued expression of BCR-ABL. Based on previous studies of normal cells, excessive exposure of the most primitive chronic myeloid leukemia cells to IL-3 and G-CSF through an autocrine mechanism could explain their paradoxically decreased self-renewal in vitro and slow accumulation in vivo, in spite of an increased cycling activity and selective expansion of later compartments.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536003      PMCID: PMC23105          DOI: 10.1073/pnas.96.22.12804

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

Authors:  T G Lugo; A M Pendergast; A J Muller; O N Witte
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

2.  Acute leukaemia in bcr/abl transgenic mice.

Authors:  N Heisterkamp; G Jenster; J ten Hoeve; D Zovich; P K Pattengale; J Groffen
Journal:  Nature       Date:  1990-03-15       Impact factor: 49.962

3.  Targeted in vivo infection with a retroviral vector carrying the interleukin-3 (multi-CSF) gene leads to immortalization and leukemic transformation of primitive hematopoietic progenitor cells.

Authors:  U Just; M Katsuno; C Stocking; E Spooncer; M Dexter
Journal:  Growth Factors       Date:  1993       Impact factor: 2.511

4.  Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia.

Authors:  A Bedi; B A Zehnbauer; J P Barber; S J Sharkis; R J Jones
Journal:  Blood       Date:  1994-04-15       Impact factor: 22.113

5.  Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.

Authors:  C A Evans; P J Owen-Lynch; A D Whetton; C Dive
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

6.  Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism.

Authors:  C Sirard; P Laneuville; J E Dick
Journal:  Blood       Date:  1994-03-15       Impact factor: 22.113

7.  Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist.

Authors:  Q Sun; J M Woodcock; A Rapoport; F C Stomski; E I Korpelainen; C J Bagley; G J Goodall; W B Smith; J R Gamble; M A Vadas; A F Lopez
Journal:  Blood       Date:  1996-01-01       Impact factor: 22.113

8.  The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion.

Authors:  S M Anderson; J Mladenovic
Journal:  Blood       Date:  1996-01-01       Impact factor: 22.113

9.  Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells.

Authors:  C J Eaves; J D Cashman; S D Wolpe; A C Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

10.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.

Authors:  B J Druker; S Tamura; E Buchdunger; S Ohno; G M Segal; S Fanning; J Zimmermann; N B Lydon
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  46 in total

Review 1.  A potential role of ruxolitinib in leukemia.

Authors:  Kiran Naqvi; Srdan Verstovsek; Hagop Kantarjian; Farhad Ravandi
Journal:  Expert Opin Investig Drugs       Date:  2011-06-03       Impact factor: 6.206

2.  IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.

Authors:  Stephane Wong; Jami McLaughlin; Donghui Cheng; Kevin Shannon; Lorraine Robb; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

3.  Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.

Authors:  Marcus Järås; Petra Johnels; Nils Hansen; Helena Agerstam; Panagiotis Tsapogas; Marianne Rissler; Carin Lassen; Tor Olofsson; Ole Weis Bjerrum; Johan Richter; Thoas Fioretos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

4.  Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.

Authors:  Xiaoyan Zhang; Huaijun Tu; Yazhi Yang; Xiaoyan Jiang; Xianliang Hu; Qidong Luo; Jian Li
Journal:  J Biol Chem       Date:  2019-06-24       Impact factor: 5.157

Review 5.  Crossing paths: interactions between the cell death machinery and growth factor survival signals.

Authors:  Gabriela Brumatti; Marika Salmanidis; Paul G Ekert
Journal:  Cell Mol Life Sci       Date:  2010-02-16       Impact factor: 9.261

6.  Distinct signaling programs control human hematopoietic stem cell survival and proliferation.

Authors:  David J H F Knapp; Colin A Hammond; Nima Aghaeepour; Paul H Miller; Davide Pellacani; Philip A Beer; Karen Sachs; Wenlian Qiao; WeiJia Wang; R Keith Humphries; Guy Sauvageau; Peter W Zandstra; Sean C Bendall; Garry P Nolan; Carl Hansen; Connie J Eaves
Journal:  Blood       Date:  2016-11-08       Impact factor: 22.113

Review 7.  The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.

Authors:  Rajesh R Nair; Joel Tolentino; Lori A Hazlehurst
Journal:  Biochem Pharmacol       Date:  2010-04-09       Impact factor: 5.858

8.  Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis.

Authors:  Mélanie Demers; Daniela S Krause; Daphne Schatzberg; Kimberly Martinod; Jaymie R Voorhees; Tobias A Fuchs; David T Scadden; Denisa D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-23       Impact factor: 11.205

9.  Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9.

Authors:  Hiroyuki Kawagoe; Gerard C Grosveld
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

10.  CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy.

Authors:  Kathleen M Sakamoto; David A Frank
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.